CDMO

Samsung Biologics Q3 2026 Results: Plant 5 Ramp-Up and Rockville Lift Revenue to KRW 1,490 Billion as 2026 Guidance Rises to 20%

By BiotechReality Business Intelligence Desk
21 October 2026

Samsung Biologics Q3 2026 Results show revenue of KRW 1,490 billion and operating profit of KRW 640 billion. Plant 5 ramp-up and the Rockville site contributed, and the company raised its 2026 revenue growth guidance to 20%.

Business CDMO Healthcare & Pharmaceuticals Manufacturing News

Samsung Biologics Q2 2026 Earnings: Revenue Rises to KRW 1,321 Billion Amid Global Manufacturing Expansion

By Editor's Desk
24 July 2026

Samsung Biologics Q2 2026 earnings rose year-over-year to KRW 1,321 billion in revenue and KRW 586 billion in operating profit, as the CDMO advanced its Rockville facility integration, Plant 5 ramp-up, and pending PolyPeptide Group acquisition.

Business CDMO Healthcare & Pharmaceuticals

Samsung Biologics Q1 2026 Results: Record Growth and Strategic U.S. Expansion

By BiotechReality Business Intelligence Desk
24 April 2026

Samsung Biologics reports a stellar start to 2026, recording KRW 1,257 billion in revenue and KRW 581 billion in operating profit, fueled by its new U.S. manufacturing presence and Plant 4 utilization.

Category: CDMO

Samsung Biologics Q3 2026 Results: Plant 5 Ramp-Up and Rockville Lift Revenue to KRW 1,490 Billion as 2026 Guidance Rises to 20%

Samsung Biologics Q2 2026 Earnings: Revenue Rises to KRW 1,321 Billion Amid Global Manufacturing Expansion

Samsung Biologics Q1 2026 Results: Record Growth and Strategic U.S. Expansion

Areas Covered

Discover More

AstraZeneca Q3 2026 Results: Total Revenue Rises 7% to $46.9bn as Oncology Leads Growth and FY2026 Guidance Holds

AbbVie Q3 2026 Results: Skyrizi, Rinvoq and Vraylar Drive $17.404 Billion Revenue as EPS Guidance Rises

Merck Daejeon Bioprocessing Center Opens With €300 Million Investment to Expand Asia-Pacific Biologics Supply

Sandoz 2026 Sales Rise 5% at CC as Biosimilars Climb 19%; Core-EBITDA Margin Guidance Upgraded to 23.0-23.5%

Novartis Q3 2026 Results: Kisqali and Kesimpta Lift Sales as Novartis Raises Full-Year Core Operating Income Guidance

IQVIA Q3 2026 Results: IQVIA Holdings Reports $4,428 Million Revenue and Raises Full-Year 2026 Guidance